← Back to charts
Oncology Nursing Drug Guide icon
APP STORE

Oncology Nursing Drug Guide

Atmosphere Apps, Inc. · Medical · United States store
NOT IN TOP 100 HERE
View on App Store ↗ Instagram card Google Play version →
Revenue a month, worldwide EST
$286
Likely $95 to $857
New ratings
Tracking
Daily counts start building from today
Rating
4.2 of 5
26 ratings in this store
Countries it ranks in
0
was 0 on Oct 18, 2026

Revenue

Estimated from the grossing charts of Oct 25, 2026 in the 53 countries we track, and ratings growth on the App Store.

EST. REVENUE / YEAR · WORLDWIDE
$3.4K
0.3 new ratings a month on average since launch
EST. LIFETIME DOWNLOADS
910 to 2.6K
Estimated from ratings count
WHERE ITS USERS ARE · SHARE OF RATINGS
  • United States 26 ratings81%
  • United Kingdom 1 ratings3%
  • Canada 1 ratings3%
  • Australia 1 ratings3%
  • Brazil 1 ratings3%
  • India 1 ratings3%
  • South Korea 1 ratings3%
HOW SURE ARE WE
Not in any grossing chart, so this comes from ratings growth (0.3 new ratings a month on average since launch): revenue grows with new ratings, more slowly for apps that collect ratings fast. Tested on 418 apps with verified revenue: typically off by about 2 times, and big earners tend to come out low. Countries we don't track (and Google Play in China, which doesn't exist) aren't included, and neither are ads or web payments. Gross revenue before store fees.
RATINGS
26
AVG RATING
4.15
PRICE
Free
AGE
8.4y
LAST UPDATE
2382d ago
VERSION
2.0.2.104
SIZE
54 MB
AGE RATING
17+

Last 30 days

From our daily snapshots of every grossing chart.

DAYS IN A GROSSING CHART
9 / 30
COUNTRIES NOW
0 (was 0)
EST. REVENUE A MONTH, DAILY · BOTH STORES EST
Show daily values
Sep 26, 2026not in a grossing chart
Sep 27, 2026not in a grossing chart
Sep 28, 2026not in a grossing chart
Sep 29, 2026not in a grossing chart
Sep 30, 2026not in a grossing chart
Oct 1, 2026not in a grossing chart
Oct 2, 2026not in a grossing chart
Oct 3, 2026not in a grossing chart
Oct 4, 2026not in a grossing chart
Oct 5, 2026not in a grossing chart
Oct 6, 2026not in a grossing chart
Oct 7, 2026not in a grossing chart
Oct 8, 2026not in a grossing chart
Oct 9, 2026not in a grossing chart
Oct 10, 2026not in a grossing chart
Oct 11, 2026not in a grossing chart
Oct 12, 2026not in a grossing chart
Oct 13, 2026not in a grossing chart
Oct 14, 2026not in a grossing chart
Oct 15, 2026not in a grossing chart
Oct 16, 2026not in a grossing chart
Oct 17, 2026not in a grossing chart
Oct 18, 2026not in a grossing chart
Oct 19, 2026not in a grossing chart
Oct 20, 2026not in a grossing chart
Oct 21, 2026not in a grossing chart
Oct 22, 2026not in a grossing chart
Oct 23, 2026not in a grossing chart
Oct 24, 2026not in a grossing chart
Oct 25, 2026not in a grossing chart
The same estimate as the headline, saved every day. Best rank Sep 26, 2026: not ranked. Now: not ranked.

Money and momentum

Measured from the store, not estimated.

WHAT IT CHARGES
1 purchase listed
  • One Year Subscription$9.99
Top in-app purchases as listed on the App Store, in local prices.
REVIEW MOMENTUM
Too few reviews
Fewer than 3 recent written reviews in this country.
RELEASE CADENCE
0 updates in 90 days
  • Typical gap between releases701 days
From the last 2 versions listed on the App Store.
RATING BREAKDOWN
26 ratings
5★69%
4★12%
3★0%
2★4%
1★15%

What users say

Latest reviews, United States App Store.

★★★★★Nov 12, 2024
Ripoff

This app crashed 30 mins into using it. I deleted it and reloaded it and it crashed again. I attempted to send an email to the tech support address and the address is no longer active. It’s too bad because it had some great info on the app for the 30 mins I was able to use it.

★★★★★Aug 26, 2023
Quick and easy to use resource

II

Apps like this

Same category, earning about as much.

Store screenshots

ScreenshotScreenshotScreenshotScreenshotScreenshotScreenshotScreenshotScreenshotScreenshotScreenshot

App Store ads

Apple Search Ads this app ran in the last 90 days, from Apple's public ad repository.

Apple's ad repository couldn't be reached right now. Try again later.

Growth research

Where this app is buying and earning its users. Each link opens pre filtered.

ASO keywords

Most repeated terms in the listing. Highlighted ones also appear in the title.

nursing5oncology nursing3nursing drug3drug handbook3turned off3drug3updated3drugs3jblearning3nurses2cancer2oncology2handbook2annually2information2chapters2understanding2indications2injection2year2turned2off2renewal2

What's new in 2.0.2.104

Updated data Framework improvements

Released May 31, 2018. Current version shipped Apr 17, 2020.

Store description

Written especially for nurses caring for patients with cancer, the Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration. Completely revised and updated, the Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs. New drugs include: apalutamide (Erleada™) calaspargase pegol-mknl (Asparlas™) Daunorubicin and cytarabine liposome for injection (Vyxeos®) glucarpidase (Voraxaze®) alpelisib (Piqray®) binimetinib (Mektovi®) dacomitinib (Vizimpro®) Duvelisib (Copiktra®) encorafenib (Braftovi®) erdafitinib (Balversa™) lorlatinib (Lorbrena®) anakinra (Kineret®) baricitinib (Olumiant®) sarilumab (Kevzara®) aprepitant injectable emulsion (Cinvanti®) granisetron hydrochloride extended-release injection (Sustol®) letermovir (Prevymis™) omadacycline (Nuzyra™) meropenem/vaborbactam (Vabomere™) Plazomicin (Zemdri™) baloxavir marboxil (Xofluza™) imipenem/cilastatin sodium/relebactam (Recarbrio™) eravacycline (Xerava™) delafloxacin (Baxdela™) Subscriptions are $9.99 for one year. Your subscription will auto-renew annually at the end of each year-long term, unless cancelled. Payment will be charged to your iTunes Account at confirmation of purchase. The subscription automatically renews unless auto-renew is turned off at least 24-hours before the end of the current period. Your account will be charged $9.99 for renewal within 24-hours prior to the end of the current period. Subscriptions may be managed and auto-renewal may be turned off by going to your Account Settings after purchase. No cancellation of the current subscription is allowed during active subscription period. Any unused portion of a free trial period, if offered, will be forfeited when the user purchases a subscription to that publication. Please see the links to our privacy policy and terms of service below. Privacy Policy - http://www.jblearning.com/privacy/ Terms of Use - http://www.jblearning.com/use/ Print Book - http://www.jblearning.com/catalog/9781284054613/

See this store page in another country

Prices, ranks and reviews are per country. Revenue above is already worldwide.

More from Atmosphere Apps, Inc.

Davis Drug Guide For Nurses
Medical
8.8K ratingsAnalyze →
FP Notebook
Medical
3.4K ratingsAnalyze →
Nurse's Drug Handbook
Medical
1.4K ratingsAnalyze →
Davis Nursing Consult
Medical
548 ratingsAnalyze →
PICU Essentials
Education
125 ratingsAnalyze →
Physicians Cancer Chemotherapy
Medical
244 ratingsAnalyze →
Guide to Clinical Midwifery
Medical
89 ratingsAnalyze →
Medical Dictionary 25th Ed.
Medical
24 ratingsAnalyze →
Davis Lab and Diagnostic Tests
Medical
2 ratingsAnalyze →